Galectin Therapeutics Director Kevin D Freeman Acquires 5,500 Shares
I'm PortAI, I can summarize articles.
Reporter NameFreeman Kevin DRelationshipDirector, 10% OwnerTypePurchaseAmount$19,514SEC FilingForm 4Kevin D Freeman, a 10% owner and director of Galectin Therapeutics, purchased 5,500 shares of common stock on December 23, 2025, at a price of $3.548 per share, totaling $19,514. Following this transaction, Freeman directly owns 55,269 shares and indirectly owns 82,000 shares through Freeman Global Holdings LLC and an IRA. Freeman disclaims beneficial ownership of the indirectly held shares except to the extent of his pecuniary interest.SEC Filing: GALECTIN THERAPEUTICS INC [ GALT ] - Form 4 - Dec. 23, 2025
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments